[{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cell","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OpRegen","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OpRegen RPE Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OPC1","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Retinal pigment epithelium cell transplant therapy","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research UK"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelium cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OPC1","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Immunomic","highestDevelopmentStatusID":"1","companyTruncated":"Lineage Cell Therapeutics \/ Immunomic"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Amasa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Cell Therapies","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Amasa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Amasa Therapeutics"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Transplant Therapy","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.67000000000000004,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Roche"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Photoreceptor Neural Cell","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"RG6501","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Hypoimmune Pluripotent Stem Cell","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IPSC-derived Cell Ttransplant Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"RG6501","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"RG6501","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Lineage Cell Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with spinal cord injuries (SCI).

                          Brand Name : AST-OPC1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 13, 2024

                          Lead Product(s) : Oligodendrocyte Progenitor Cell Therapy-1

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with spinal cord injuries (SCI).

                          Brand Name : AST-OPC1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 18, 2023

                          Lead Product(s) : Oligodendrocyte Progenitor Cell Therapy-1

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

                          Brand Name : OpRegen

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 05, 2023

                          Lead Product(s) : RG6501

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

                          Brand Name : OpRegen

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 13, 2023

                          Lead Product(s) : RG6501

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The novel hypoimmune iPSC line is a targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 06, 2023

                          Lead Product(s) : IPSC-derived Cell Ttransplant Therapy

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : Eterna Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.

                          Brand Name : AST-VAC2

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          July 24, 2023

                          Lead Product(s) : AST-VAC2

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Cancer Research

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Eterna will develop the novel induced hypoimmune pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into cell transplant therapies and for the treatment of certain CNS disorders and other neurology indica...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 22, 2023

                          Lead Product(s) : Hypoimmune Pluripotent Stem Cell

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : Eterna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : In Phase 1/2a clinical trial, RG6501 (OpRegen) demonstrated the potential to slow, stop, or reverse the progression of GA in patients with GA. These results can be maintained beyond one year following a one-time, approximately 30-minute outpatient proced...

                          Brand Name : OpRegen

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 28, 2022

                          Lead Product(s) : RG6501

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AST-OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with acute spinal cord injuries (SCI).

                          Brand Name : AST-OPC1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 10, 2022

                          Lead Product(s) : Oligodendrocyte Progenitor Cell Therapy-1

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The majority of AEs reported with RG6501, OpRegen (allogeneic retinal pigment epithelial cells) were mild (Cohort 1-3, 87%; Cohort 4, 93%), and the immunosuppressive regimen was well tolerated, for the treatment of geographic atrophy.

                          Brand Name : OpRegen

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 03, 2022

                          Lead Product(s) : Allogeneic Retinal Pigment Epithelial Cells

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank